Satellos to Participate in Two April Investor Conferences
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF), a clinical-stage biotechnology company focused on developing treatments for degenerative muscle diseases, has announced its participation in two major investor conferences in April 2025.
The company will deliver a presentation at the Oppenheimer Innovation on the Island conference in San Juan, Puerto Rico on April 10, 2025, at 10:08 a.m. AST. Additionally, Satellos will participate in one-on-one meetings at the Piper Sandler Spring Biopharma Symposium in Boston, MA on April 16, 2025.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di trattamenti per le malattie muscolari degenerative, ha annunciato la sua partecipazione a due importanti conferenze per investitori nell'aprile 2025.
L'azienda presenterà una relazione alla conferenza Oppenheimer Innovation on the Island a San Juan, Porto Rico, il 10 aprile 2025, alle 10:08 AST. Inoltre, Satellos parteciperà a incontri one-to-one al Piper Sandler Spring Biopharma Symposium a Boston, MA, il 16 aprile 2025.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF), una empresa de biotecnología en etapa clínica centrada en el desarrollo de tratamientos para enfermedades musculares degenerativas, ha anunciado su participación en dos importantes conferencias de inversores en abril de 2025.
La empresa realizará una presentación en la conferencia Oppenheimer Innovation on the Island en San Juan, Puerto Rico, el 10 de abril de 2025, a las 10:08 a.m. AST. Además, Satellos participará en reuniones uno a uno en el Piper Sandler Spring Biopharma Symposium en Boston, MA, el 16 de abril de 2025.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF)는 퇴행성 근육 질환 치료제 개발에 주력하는 임상 단계의 생명공학 회사로, 2025년 4월 두 개의 주요 투자자 회의에 참여할 것이라고 발표했습니다.
회사는 2025년 4월 10일 오전 10시 8분 AST에 푸에르토리코 산후안에서 열리는 Oppenheimer Innovation on the Island 회의에서 발표를 진행합니다. 또한, Satellos는 2025년 4월 16일 매사추세츠주 보스턴에서 열리는 Piper Sandler Spring Biopharma Symposium에서 일대일 회의에 참여할 예정입니다.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF), une entreprise de biotechnologie en phase clinique axée sur le développement de traitements pour les maladies musculaires dégénératives, a annoncé sa participation à deux grandes conférences pour investisseurs en avril 2025.
L'entreprise fera une présentation lors de la conférence Oppenheimer Innovation on the Island à San Juan, Porto Rico, le 10 avril 2025, à 10h08 AST. De plus, Satellos participera à des réunions individuelles lors du Piper Sandler Spring Biopharma Symposium à Boston, MA, le 16 avril 2025.
Satellos Bioscience (TSX: MSCL, OTCQB: MSCLF), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für degenerative Muskelerkrankungen konzentriert, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im April 2025 bekannt gegeben.
Das Unternehmen wird am 10. April 2025 um 10:08 Uhr AST eine Präsentation auf der Konferenz Oppenheimer Innovation on the Island in San Juan, Puerto Rico, halten. Darüber hinaus wird Satellos an Einzelgesprächen auf dem Piper Sandler Spring Biopharma Symposium in Boston, MA, am 16. April 2025 teilnehmen.
- None.
- None.
Oppenheimer Innovation on the Island
Format: Presentation
Date: Thurs., April 10, 2025, 10:08 a.m. AST
Location:
Piper Sandler Spring Biopharma Symposium
Format: Participation in 1x1 meetings
Date: Wed., April 16, 2025
Location:
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit www.satellos.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250402985439/en/
Investors: Liz Williams, CFO, ir@satellos.com
Media: Emily Williams, Senior Director, Communications, eawilliams@satellos.com
Clinical Trial Info: medicalinfo@satellos.com
Source: Satellos Bioscience Inc.
FAQ
What investor conferences will MSCLF attend in April 2025?
When and where is Satellos Bioscience (MSCLF) presenting at the Oppenheimer conference?
What type of meetings will MSCLF conduct at the Piper Sandler symposium?
What is the primary focus of Satellos Bioscience's (MSCLF) drug development?
